Our aim – To meet the needs of our customers through access to our next generation platform technologies, enabling rapid discovery, optimization and development of leading edge recombinant monoclonal antibody therapies. Our ultimate aim is to be the preferred partner for the development of next generation therapeutic monoclonal antibodies. Hence, we seek to provide an enhanced value proposition to our biopharmaceutical and academic partners.

Our work – To design a new generation of diagnostic and therapeutic antibodies for the study or treatment of diseases. Nearly everything we do entails a non-traditional approach to problem solving that requires innovative, unconventional thinking. We are visionary and ambitious, challenging both ourselves and others. We believe our progress is necessarily linked to our ability to think differently and reframe problems as opportunities.

Our services – To provide rapid access at flexible rates to a variety of high quality monoclonal antibodies of research, diagnostic or therapeutic significance